Sees FY24 revenue $9.35B-$9.45B, consensus $9.39B. Davis continued: “Our guidance for 2024 reflects a return to overall revenue growth while balancing the earnings tailwinds and headwinds we see for the year. Looking beyond 2024, we are well positioned to deliver our long-term financial outlook to drive mid-single digit revenue growth and high-single digit earnings growth. Finally, I’m grateful to our dedicated Quest colleagues who bring our purpose to life every day, working together to create a healthier world, one life at a time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- DGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quest Diagnostics price target lowered to $152 from $153 at JPMorgan
- Quest Diagnostics and Fitbit announce collaboration to study wearable devices
- Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System